Stevanato Group (STVN) AI Stock Analysis

Compare

126 Followers

Top Page

Stevanato Group

(NYSE:STVN)

Rating:65Neutral

Price Target:

$25.00

▲(5.80% Upside)

Stevanato Group's overall stock score reflects solid financial performance and a positive earnings call, tempered by technical indicators suggesting bearish momentum and a high valuation. The company's focus on growth and operational improvements are positive, but challenges in certain segments and tariff impacts present risks.

Positive Factors

Earnings

Stevanato reported strong second-quarter results, beating both estimates and consensus.

Facility and Operations

Stevanato's facility in Fishers, Indiana, is strategically located next to key customers, enabling supply chain optimization, reduced risk, and increased product integrity.

Revenue Growth

Revenue growth returned to high single digits including 25% HVS growth, and with destocking fading, vial orders were up double digits.

Negative Factors

Engineering Division

Engineering revenue declined by 4% year over year due to lower sales from visual inspection and glass conversion lines.

FX and Tariffs

Despite an incremental headwind from FX and tariffs, full-year guidance was maintained.

Guidance and Margins

Margins suffered from mix and guidance was reduced due to new project delays in Engineering.

Stevanato Group (STVN) vs. SPDR S&P 500 ETF (SPY)

Market Cap

$6.45B

Dividend Yield0.26%

Average Volume (3M)328.53K

Price to Earnings (P/E)44.1

Beta (1Y)0.62

Revenue Growth5.95%

EPS Growth7.73%

CountryUS

Employees5,521

SectorHealthcare

Sector Strength38

IndustryMedical - Instruments & Supplies

Share Statistics

EPS (TTM)0.13

Shares Outstanding49,604,650

10 Day Avg. Volume478,267

30 Day Avg. Volume328,534

Financial Highlights & Ratios

PEG Ratio-2.23

Price to Book (P/B)4.09

Price to Sales (P/S)5.20

P/FCF Ratio-36.39

Enterprise Value/Market Cap1.09

Enterprise Value/Revenue6.26

Enterprise Value/Gross Profit23.03

Enterprise Value/Ebitda25.25

Forecast

1Y Price Target

$27.80

Price Target Upside17.65% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering6

Stevanato Group Business Overview & Revenue Model

Company DescriptionStevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for pharma and healthcare. Its principal products include containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machines. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. operates as a subsidiary of Stevanato Holding S.R.L.

How the Company Makes MoneyStevanato Group generates revenue primarily through the manufacturing and sale of its proprietary glass and plastic products, which are essential components for the pharmaceutical and biotechnology sectors. The company offers a wide range of solutions, including glass vials, syringes, cartridges, and customized plastic products, which are used for the containment and delivery of drugs. Revenue streams are bolstered by long-term contracts and partnerships with major pharmaceutical companies, which rely on Stevanato’s products for their drug manufacturing and delivery processes. Additionally, the company provides value-added services such as analytical testing and regulatory support, enhancing its revenue potential. Significant factors contributing to its earnings include its advanced manufacturing capabilities, strong intellectual property portfolio, and global distribution network, enabling it to effectively meet the needs of a diverse client base.

Stevanato Group Earnings Call Summary

Earnings Call Date:Aug 05, 2025

(Q1-2025)

% Change Since: -7.62%|

Next Earnings Date:Nov 11, 2025

Earnings Call Sentiment Positive

The earnings call reflects a positive start to fiscal 2025 with robust revenue growth and operational improvements in the BDS segment. However, challenges remain in the Engineering segment and due to tariff impacts. The positive aspects slightly outweigh the negatives, indicating a cautiously optimistic outlook for the year.

Q1-2025 Updates

Positive Updates

Strong Revenue Growth

The company reported a 9% increase in revenue in the first quarter of 2025, driven by a strong performance in the Biopharmaceutical and Diagnostics Solutions Segment.

High-Value Solutions Growth

Revenue from high-value solutions grew 25% in the first quarter to EUR 110.3 million, accounting for 43% of total revenue.

Operational Improvements in BDS Segment

The BDS segment saw an 11% growth in revenue, supported by improvements at Latina and Fishers facilities.

Margin Expansion

Consolidated gross profit margin increased by 80 basis points to 27.2%, while operating profit margin increased by 280 basis points to 13.5%.

Order Intake Growth

Double-digit growth in order intake for both bulk and sterile vials compared to the previous year.

Negative Updates

Engineering Segment Revenue Decline

Revenue from the Engineering segment decreased by 4% due to lower sales from pharmaceutical visual inspection and glass conversion lines.

Margins Impacted by Legacy Projects

Engineering segment's gross profit margins were below expectations, decreasing to 10.7% due to unfavorable project mix related to legacy projects in Denmark.

Tariff Impact

Estimated EUR 4.5 million impact on operating profit due to tariffs, affecting earnings per share by approximately EUR 0.01.

Company Guidance

In the Stevanato Group's first quarter 2025 results call, the company reported a 9% revenue growth, reaching EUR 256.6 million, driven by an 11% increase in the Biopharmaceutical and Diagnostics Solutions (BDS) segment, which offset a 4% decline in the Engineering segment. High-value solutions, including a partial recovery in EZ-fill vials, accounted for 43% of total revenue, growing 25% year-over-year to EUR 110.3 million. The company's gross profit margin increased by 80 basis points to 27.2%, while the operating profit margin rose by 280 basis points to 13.5%. Adjusted EBITDA was EUR 57.4 million, with a margin improvement of 100 basis points to 22.4%. The company also updated its full-year guidance, expecting revenue between EUR 1.160 billion and EUR 1.190 billion and adjusted EBITDA between EUR 288.5 million and EUR 301.8 million, factoring in an anticipated EUR 4.5 million impact from tariffs.

Stevanato Group Financial Statement Overview

Summary

Stevanato Group shows strong revenue growth and efficient cost management, with stable profitability and balance sheet. The firm is financially solid but needs improvements in cash management due to negative free cash flow from high capital expenditures.

Income Statement

Very Positive

Stevanato Group has demonstrated consistent revenue growth with a TTM (Trailing-Twelve-Months) increase from the previous year. Gross Profit Margin is strong at 27.18%, reflecting efficient cost management in production. Net Profit Margin stands at 11.16%, indicating solid profitability. EBIT and EBITDA margins are healthy, at 15.16% and 24.80%, respectively, signaling effective operational performance. The company shows a robust growth trajectory, with some room for improvement in net profit margins.

Balance Sheet

Positive

The company's Debt-to-Equity Ratio is 0.28, indicating a conservative leverage strategy, which reduces financial risk. Return on Equity (ROE) is 8.86%, reflecting moderate efficiency in using equity to generate profit. Equity Ratio is 60.91%, which is a healthy sign of financial stability and lower risk. Overall, the balance sheet shows solid stability with potential for improving returns.

Cash Flow

Positive

Operating Cash Flow to Net Income Ratio is 1.47, suggesting healthy cash generation relative to net income. However, the Free Cash Flow remains negative, indicating high capital expenditures possibly for growth, which affects short-term cash availability. Free Cash Flow to Net Income Ratio is negative, reflecting a need for better cash management despite good operational cash flow.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.12B	1.10B	1.09B	983.70M	843.90M	662.04M
Gross Profit	305.87M	302.32M	339.89M	319.80M	265.40M	194.18M
EBITDA	278.95M	247.80M	272.35M	256.40M	226.93M	156.38M
Net Income	125.48M	117.78M	145.63M	142.85M	134.32M	78.51M
Balance Sheet
Total Assets	2.32B	2.33B	2.07B	1.66B	1.42B	967.98M
Cash, Cash Equivalents and Short-Term Investments	90.72M	98.27M	72.18M	256.65M	438.21M	157.12M
Total Debt	393.35M	428.97M	396.59M	218.37M	244.29M	363.01M
Total Liabilities	908.28M	924.43M	938.93M	663.79M	577.18M	657.84M
Stockholders Equity	1.42B	1.40B	1.13B	995.90M	841.70M	310.50M
Cash Flow
Free Cash Flow	-98.62M	-157.79M	-336.72M	-139.83M	20.12M	59.65M
Operating Cash Flow	184.02M	155.78M	105.21M	103.30M	133.30M	155.66M
Investing Cash Flow	-278.81M	-310.21M	-421.22M	-243.00M	-96.40M	-96.09M
Financing Cash Flow	606.00K	183.22M	158.03M	-44.50M	254.80M	-26.52M

Stevanato Group Technical Analysis

Technical Analysis Sentiment

Neutral

Last Price23.63

Price Trends

50DMA

24.45

Negative

100DMA

23.12

Positive

200DMA

21.95

Positive

Market Momentum

MACD

-0.16

Positive

RSI

43.72

Neutral

STOCH

23.25

Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For STVN, the sentiment is Neutral. The current price of 23.63 is below the 20-day moving average (MA) of 25.11, below the 50-day MA of 24.45, and above the 200-day MA of 21.95, indicating a neutral trend. The MACD of -0.16 indicates Positive momentum. The RSI at 43.72 is Neutral, neither overbought nor oversold. The STOCH value of 23.25 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for STVN.

Stevanato Group Risk Analysis

Stevanato Group disclosed 63 risk factors in its most recent earnings report. Stevanato Group reported the most risks in the "Finance & Corporate" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added 0 New Risks

Stevanato Group Peers Comparison

Overall Rating

UnderperformOutperform

Sector (46)

Financial Indicators

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TFX	73 Outperform	$5.23B	27.87	4.36%	1.15%	1.11%	-23.73%
MMSI	72 Outperform	$5.07B	43.48	8.60%	―	10.14%	0.04%
STVN	65 Neutral	$6.45B	44.14	9.55%	0.26%	5.95%	7.73%
ICUI	61 Neutral	$2.79B	―	-1.78%	―	2.95%	47.92%
RGEN	56 Neutral	$6.27B	―	-0.68%	―	8.73%	-245.82%
BLCO	54 Neutral	$4.83B	―	-4.22%	―	8.81%	40.43%
Sector *	46 Neutral	C$193.30M	-2.83	-24.76%	3.14%	19.77%	0.53%

* Healthcare Sector Average

Performance Comparison

STVN

Stevanato Group

23.63

3.77

18.98%

ICUI

ICU Medical

112.85

-35.22

-23.79%

MMSI

Merit Medical Systems

85.58

-4.63

-5.13%

RGEN

Repligen

111.43

-52.15

-31.88%

TFX

Teleflex

118.41

-107.99

-47.70%

BLCO

Bausch + Lomb Corporation

13.64

-1.87

-12.06%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 06, 2025